On September 10, 2026, Teitur Trophics, an Aarhus University spin-out in Aarhus, Denmark, said its lead peptide TT-P34 cleared a first-in-human safety and pharmacokinetics bar. The BioSpace copy of the GlobeNewswire release and the same text on Teitur's Parkinson pipeline page report a randomized, double-blind, placebo-controlled Phase I study at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands.
The company topline is a safety, exposure, and biomarker-trend package. It is not Parkinson's disease efficacy. It is not disease modification. It is not FDA approval. TT-P34 remains investigational.
This is the 10:07 Research Roundup. It is not an Industry News incretin story. TT-P34 is not SS-31 (elamipretide). Sharing a mitochondrial conversation is not sharing a molecule. It is not ARA-290.
Andreas Borta, Teitur's chief medical officer, called TT-P34 potentially a "game-changer" for Parkinson's and other neurodegenerative diseases. That is company language. PeptidePrices does not adopt it.
What happened on September 10
Teitur announced "successful results" from Phase I of TT-P34 in healthy volunteers and patients with early-stage Parkinson's disease. The company release says the readout supports a Phase II trial in Parkinson's patients in 2027, designed to explore therapeutic benefit and disease-modifying potential. A planned Phase II is a next-step statement. It is not a Phase II result.
Simon Mølgaard, co-founder and CEO, said Teitur is fundraising for a Series B ahead of that planned Phase II. The same release repeats a company figure of more than 10 million people worldwide living with Parkinson's and says current treatment still manages symptoms.
MedPath and cGxP.wire recapped the same September 10 numbers. They are secondary. They do not add an independent patient-level dataset.
The Phase I data are scheduled for the International Congress of Parkinson's Disease and Movement Disorders in Seoul, 4-8 October 2026. Teitur names Monday 5 October, 9:30-9:40, E-Poster Hall D, Station 12. That is a presentation slot, not a peer-reviewed Phase I paper.
A ClinicalTrials.gov search on 11 September 2026 for TT-P34, Teitur, and Teitur Trophics returned no studies. The trial site is CHDR in the European Union. This article does not invent an NCT.
What TT-P34 is
Teitur describes TT-P34 as a first-in-class cyclic, or macrocyclic, peptide derived from SorCS2, a VPS10p-domain receptor. The company mechanism copy says the peptide is meant to reactivate CREB in neurons and thereby improve mitochondrial and lysosomal function. That is the sponsor's pathway story. It is not a Phase I clinical-efficacy claim.
The independent primary preclinical source is Dalby et al., Acta Neuropathologica Communications, published 10 August 2026 (doi 10.1186/s40478-026-02403-x; Springer OA page). The journal labels it early-access accepted research: citable, permanent DOI, still subject to Version-of-Record edits. This article uses the fetched abstract plus funding, affiliation, and competing-interest blocks. Springer PDF endpoints returned HTML stubs, so full text was not retrieved.
The abstract says SorCS2-derived macrocyclic peptides activate CREB and AMPK, possibly via CAMKK2, and upregulate PGC1α and TFEB. In zQ175 Huntington mice, lipidated TT-P34 is reported to rescue motor and behavioral deficits and preserve striatal synaptic and mitochondrial signatures. In MPTP Parkinson mice, it is reported to ameliorate motor deficits and preserve dopaminergic neurons. The authors also report NHP blood-brain-barrier crossing and estimate a human therapeutic regimen by pharmacodynamic modelling. That modelled estimate is not an approved human dose. The abstract prints no milligram figure for it.
Dalby, Kaas, Mølgaard, and Glerup list Teitur and Aarhus University. The paper says they invented SorCS2-derived peptide-mimetic patents and have significant financial interests in Teitur, which holds exclusive rights to two patents on modulated SorCS2 intracellular-domain mimetics. Neil Benson, Emily Roashan, Keld Fosgerau, Kristian Strømgaard, and a consultant initialled SLB "have been compensated as consultants by Teitur Trophics for their contributions to work included in this paper." Funding includes Novo Nordisk Foundation grant NNF18OC003307 to Simon Mølgaard and Teitur Trophics ApS.
That is peer-reviewed preclinical work with disclosed patents, equity, consulting pay, and sponsor funding. It does not confirm the September Phase I topline. It is not a human Parkinson's efficacy paper.
Teitur's pipeline page reprints a 14 March 2023 Series A of €28 million, co-led by Sunstone Life Science Ventures and Sound Bioventures. That is financing history, not a Phase I result.
A COA check can test whether a certificate names a real lab. It cannot turn a catalog vial into Teitur's investigational peptide. TT-P34 is not approved for human use.
| Thing | What it is | What Phase I can show |
|---|---|---|
| SorCS2 | VPS10p-domain receptor with claimed neurotrophic signaling | Target rationale, not a human outcome |
| TT-P34 | Lipidated SorCS2-derived macrocyclic peptide (Dalby 2026; Teitur) | Safety, PK, CSF biomarker trends |
| Phase I at CHDR | Randomized, double-blind, placebo-controlled, weekly SC | Tolerability and exposure in volunteers and 12 PD patients |
| CSF lysosomal panel | Company-developed mechanism biomarkers | Early pathway-modulation signal, company-described |
| Disease modification | Slowing or stopping PD progression in a powered trial | Not this study |
Study design
The September 10 release describes a randomized, double-blind, placebo-controlled Phase I at CHDR, Leiden. Enrollment was 55 healthy volunteers, then 12 patients with early-stage Parkinson's disease. The healthy-volunteer split was 31 in single ascending dose (SAD) and 24 in multiple ascending dose (MAD).
The PD extension, from Teitur's 28 May 2026 completion note on the same pipeline page, used four weeks of treatment and a four-week safety follow-up, with three lumbar punctures for cerebrospinal fluid. The September topline later calls the PD window a ~50-day study. Those clocks sit on the same company site. This article keeps both.
Route is once-weekly subcutaneous TT-P34. The company says the peptide was safe and well tolerated at all doses tested, with no dose-limiting findings, including when given with standard levodopa in the PD cohort. Numeric milligram dose levels were not published in the September 10 topline. This article does not invent them.
| Item | Published figure | Source |
|---|---|---|
| Phase | I, first-in-human | Teitur / BioSpace, 10 Sept 2026 |
| Design | Randomized, double-blind, placebo-controlled | Teitur / BioSpace |
| Site | CHDR, Leiden, Netherlands | Teitur / BioSpace |
| Healthy volunteers | 55 (31 SAD, 24 MAD) | Teitur / BioSpace |
| PD cohort | 12 early-stage Parkinson's patients | Teitur / BioSpace |
| Route | Once-weekly subcutaneous | Teitur / BioSpace |
| Numeric mg levels | Not disclosed in the Sept. 10 topline | Teitur / BioSpace |
| PD treatment + follow-up | Four weeks on drug, four-week safety follow-up | Teitur, 28 May 2026 |
| CSF sampling | Three lumbar punctures | Teitur, 28 May 2026 |
| PD study window in topline | Over the 50-day study | Teitur / BioSpace, 10 Sept 2026 |
| ClinicalTrials.gov NCT | None found on 11 Sept 2026 | ClinicalTrials.gov search |
What the numbers show
Safety, as reported. The company says once-weekly subcutaneous TT-P34 was safe and well tolerated at all doses tested, with no dose-limiting findings. It also says the peptide was well tolerated on top of levodopa in the PD cohort. Those sentences are sponsor topline. They are not a published adverse-event table, and they are not a disease-modification result.
Pharmacokinetics, as reported. Teitur says TT-P34 crosses the blood-brain barrier, with robust, dose-dependent exposure in brain and CNS, and that the results support weekly dosing. "Support weekly dosing" is a PK interpretation. It is not an approved regimen.
Biomarkers, as reported. Teitur says the trial let it build a CSF panel of mechanism-related biomarkers. Over the ~50-day PD window, "the majority of PD patients who received TT-P34" showed a coordinated response across multiple lysosomal proteins in CSF. The company calls that an early signal that the intended lysosomal, and by extension mitochondrial, pathway was modulated. A coordinated CSF protein trend is not a motor-score win. It is not clinical efficacy.
No milligram dose, no placebo-adjusted CSF effect size, no UPDRS change, and no peer-reviewed Phase I paper appear in the September 10 materials fetched for this article. MedPath and cGxP.wire repeat the same company sentences. They do not fill those gaps.
Trial doses
TT-P34 is not approved for human use. The table reports what the company published. It is not a dosage guide and it is not a consumer protocol.
| Setting | Reported exposure | Source |
|---|---|---|
| Phase I route | Once-weekly subcutaneous injection | Teitur / BioSpace, 10 Sept 2026 |
| SAD / MAD / PD cohorts | "All doses tested"; numeric mg levels not disclosed | Teitur / BioSpace |
| PD duration | Four weeks of treatment, then four-week safety follow-up | Teitur, 28 May 2026 |
| Paper modelling | Human therapeutic regimen estimated by pharmacodynamic modelling; no milligram figure in the fetched abstract | Dalby et al., 10 Aug 2026 |
Every dose section in this article is a trial assignment or a modelled preclinical estimate. TT-P34 is not approved for human use. That does not make weekly SC an approved dose. If a later peer-reviewed Phase I paper or a public registry lists milligrams, cite that paper. Until then, leave the milligrams undisclosed.
Research-vendor vials, if they appear later, are not the CHDR study drug. Price is not identity. Use the vendor checklist and the COA verification guide before treating any certificate as proof.
Preclinical package limits
Dalby et al. is the required independent primary for the animal story. Independent here means peer-reviewed and separate from the September press release. It does not mean free of company interest.
The abstract's Huntington and MPTP mouse claims are animal data. Motor rescue in zQ175 or MPTP is not a human Parkinson's result. Striatal synaptic and mitochondrial signatures are tissue readouts in mice. NHP blood-brain-barrier crossing is primate PK, not a patient outcome. The pharmacodynamic human-dose model is a model. The authors' closing line, that the findings support TT-P34 as a novel disease-modifying therapy, is the paper's interpretation. PeptidePrices does not upgrade it to a clinical fact.
No fetched abstract number is treated as a human milligram. No catalog protocol is inferred from MPTP or zQ175.
What this does not mean
- It is not disease modification. Phase I did not test whether TT-P34 slows Parkinson's. The company says Phase II, planned for 2027, will explore that question.
- It is not clinical efficacy. No fetched source publishes a powered motor, quality-of-life, or progression endpoint.
- CSF lysosomal trends are not a treatment win. A company-described coordinated response in a 12-patient PD cohort is an early mechanistic signal.
- It is not FDA approval. TT-P34 is investigational. It is not approved for Parkinson's or any other use.
- Weekly subcutaneous is not a labeled dose. The topline omitted numeric milligrams. That does not make weekly SC an approved dose.
- A modelled human regimen is not a protocol. Dalby et al. estimate a regimen from pharmacodynamic modelling. The abstract does not print the number.
- "Game-changer" is a quote, not a finding. It is Borta's language in the company release.
- The August paper does not confirm the September topline. It is preclinical, company-affiliated, and earlier.
- This is not medical advice, and it is not a consumer dosing protocol.
- This is not a GLP-1, GIP, or amylin rewrite.
What did not change
TT-P34's unapproved status did not change on 11 September 2026. No PeptidePrices research page was created or updated. No catalog vial became the CHDR study drug.
Absence of a ClinicalTrials.gov NCT is a documentation gap, not proof the Leiden trial did not happen.
Limitations
The September 10 package is a company press release. No peer-reviewed Phase I manuscript was fetched. Numeric doses, PD-cohort placebo counts, adverse-event grades, and CSF protein names are unpublished in that topline. The biomarker claim is qualitative: "majority," "coordinated response," "clear trends."
Dalby et al. is early-access accepted text. This article stays inside the fetched abstract and declarations. MedPath and cGxP.wire recap the same release. They are not a second trial.
What to watch next
- The MDS Seoul e-poster, 5 October 2026. Look for the first public tables: milligram levels, AE counts, and named CSF proteins. A slide is still not a journal paper.
- A peer-reviewed Phase I write-up. Safety plus PK plus biomarkers need methods, randomization splits, and statistics that a press release does not carry.
- A public trial registration. If an NCT or EU CTIS record appears, that is the place to read inclusion criteria and endpoints. None was found on 11 September 2026.
- Phase II design in 2027. Disease modification requires a powered clinical endpoint, not another CSF trend. Financing a Series B does not enroll that trial.
- How later copy treats the August paper. Mouse MPTP and zQ175 results stay preclinical even after a clean Phase I safety readout.
FAQs
Is TT-P34 FDA-approved?
No. It is an investigational peptide. It is not approved for Parkinson's disease or any other use.
Did Phase I prove TT-P34 treats Parkinson's?
No. The company reported tolerability, weekly-dosing PK, and CSF lysosomal trends in 12 early-stage patients. That is not clinical efficacy and not disease modification.
What dose was used?
The September 10 topline did not publish numeric milligram levels. The route was once-weekly subcutaneous injection. TT-P34 is not approved for human use. That does not make weekly SC an approved dose.
Is there a ClinicalTrials.gov NCT?
Not in the 11 September 2026 searches used for this article. Queries for TT-P34, Teitur, and Teitur Trophics returned no studies. The Phase I site was CHDR in Leiden.
What did the August 2026 paper show?
Dalby et al. report mouse Huntington and MPTP Parkinson models, NHP BBB crossing, and a modelled human regimen, with CREB/AMPK and PGC1α/TFEB claims in the abstract. Authors include Teitur inventors with patents and equity. That paper is not the Phase I readout.
This article is for general informational purposes only and is not medical advice. Talk to a licensed clinician about personal medical decisions. TT-P34 is an investigational peptide studied in a company-reported Phase I trial. Nothing here is a dosing protocol, an availability claim, or a recommendation to obtain an unapproved product.
Continue your research
- SS-31 (elamipretide) mitochondrial peptide
- ARA-290 human trial doses
- How to verify a peptide COA
- Vendor checklist
- COA Authenticity Checker
Sources
- Teitur Trophics. Successful results from Phase I clinical trial of TT-P34. GlobeNewswire / BioSpace. 10 September 2026
- Teitur Trophics. Parkinson's and neurodegeneration pipeline (Phase I release, 28 May 2026 PD-cohort note, 14 March 2023 Series A). Accessed 11 September 2026
- Dalby A, et al. The SorCS2-derived macrocycle TT-P34 drives neuroprotection in animal models of neurodegeneration. Acta Neuropathol Commun. Published 10 August 2026. doi 10.1186/s40478-026-02403-x
- Springer Nature OA page for Dalby et al., doi 10.1186/s40478-026-02403-x
- MedPath. Teitur Trophics' first-in-class peptide TT-P34 clears Phase I in Parkinson's, confirming brain exposure. 10 September 2026
- cGxP.wire. Teitur Trophics advances TT-P34 toward Phase II in Parkinson's. 11 September 2026
- ClinicalTrials.gov search for TT-P34, queried 11 September 2026